Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Jensen, PEH, Warnke, C, Ingenhoven, K, Piccoli, L, Gasis, M, Hermanrud, C, Fernandez-Rodriguez, BM, Ryner, M, Kramer, D, Link, J, Ramanujam, R, Auer, M, Buck, D, Grummel, V, Bertotti, E, Fissolo, N, Oliver-Martos, B, Nytrova, P, Khalil, M, Guger, M, Rathmaier, S, Sievers-Stober, C, Lindberg, RLP, Hässler, S, Bachelet, D, Aktas, O, Donnellan, N, Lawton, A, Hemmer, B, Havrdova, EK, Kieseier, B, Hartung, H-P, Comabella, M, Montalban, X, Derfuss, T, Sellebjerg, F, Dönnes, P, Pallardy, M, Spindeldreher, S, Broët, P, Deisenhammer, F, Fogdell-Hahn, A, Sorensen, PS & ABIRISK Consortium 2019, 'Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study', Journal of Neuroimmunology, bind 326, s. 19-27. https://doi.org/10.1016/j.jneuroim.2018.11.002

APA

Jensen, P. E. H., Warnke, C., Ingenhoven, K., Piccoli, L., Gasis, M., Hermanrud, C., Fernandez-Rodriguez, B. M., Ryner, M., Kramer, D., Link, J., Ramanujam, R., Auer, M., Buck, D., Grummel, V., Bertotti, E., Fissolo, N., Oliver-Martos, B., Nytrova, P., Khalil, M., ... ABIRISK Consortium (2019). Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 326, 19-27. https://doi.org/10.1016/j.jneuroim.2018.11.002

CBE

Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, Sievers-Stober C, Lindberg RLP, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung H-P, Comabella M, Montalban X, Derfuss T, Sellebjerg F, Dönnes P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS, ABIRISK Consortium. 2019. Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology. 326:19-27. https://doi.org/10.1016/j.jneuroim.2018.11.002

MLA

Vancouver

Author

Jensen, Poul Erik H ; Warnke, Clemens ; Ingenhoven, Kathleen ; Piccoli, Luca ; Gasis, Marcia ; Hermanrud, Christina ; Fernandez-Rodriguez, Blanca M ; Ryner, Malin ; Kramer, Daniel ; Link, Jenny ; Ramanujam, Ryan ; Auer, Michael ; Buck, Dorothea ; Grummel, Verena ; Bertotti, Elisa ; Fissolo, Nicolas ; Oliver-Martos, Begoña ; Nytrova, Petra ; Khalil, Michael ; Guger, Michael ; Rathmaier, Sandra ; Sievers-Stober, Claudia ; Lindberg, Raija L P ; Hässler, Signe ; Bachelet, Delphine ; Aktas, Orhan ; Donnellan, Naoimh ; Lawton, Andy ; Hemmer, Bernhard ; Havrdova, Eva Kubala ; Kieseier, Bernd ; Hartung, Hans-Peter ; Comabella, Manuel ; Montalban, Xavier ; Derfuss, Tobias ; Sellebjerg, Finn ; Dönnes, Pierre ; Pallardy, Marc ; Spindeldreher, Sebastian ; Broët, Philippe ; Deisenhammer, Florian ; Fogdell-Hahn, Anna ; Sorensen, Per Soelberg ; ABIRISK Consortium. / Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. I: Journal of Neuroimmunology. 2019 ; Bind 326. s. 19-27.

Bibtex

@article{cc239d06b5ee4b1db2f21fa41e8d56a1,
title = "Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study",
abstract = "Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.",
keywords = "Antibodies, Neutralizing/blood, Biological Assay, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunologic Factors/immunology, Interferon-beta/immunology, Male, Multiple Sclerosis/blood, Neutralization Tests/methods",
author = "Jensen, {Poul Erik H} and Clemens Warnke and Kathleen Ingenhoven and Luca Piccoli and Marcia Gasis and Christina Hermanrud and Fernandez-Rodriguez, {Blanca M} and Malin Ryner and Daniel Kramer and Jenny Link and Ryan Ramanujam and Michael Auer and Dorothea Buck and Verena Grummel and Elisa Bertotti and Nicolas Fissolo and Bego{\~n}a Oliver-Martos and Petra Nytrova and Michael Khalil and Michael Guger and Sandra Rathmaier and Claudia Sievers-Stober and Lindberg, {Raija L P} and Signe H{\"a}ssler and Delphine Bachelet and Orhan Aktas and Naoimh Donnellan and Andy Lawton and Bernhard Hemmer and Havrdova, {Eva Kubala} and Bernd Kieseier and Hans-Peter Hartung and Manuel Comabella and Xavier Montalban and Tobias Derfuss and Finn Sellebjerg and Pierre D{\"o}nnes and Marc Pallardy and Sebastian Spindeldreher and Philippe Bro{\"e}t and Florian Deisenhammer and Anna Fogdell-Hahn and Sorensen, {Per Soelberg} and {ABIRISK Consortium}",
note = "Copyright {\textcopyright} 2018 Elsevier B.V. All rights reserved.",
year = "2019",
month = jan,
day = "15",
doi = "10.1016/j.jneuroim.2018.11.002",
language = "English",
volume = "326",
pages = "19--27",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study

AU - Jensen, Poul Erik H

AU - Warnke, Clemens

AU - Ingenhoven, Kathleen

AU - Piccoli, Luca

AU - Gasis, Marcia

AU - Hermanrud, Christina

AU - Fernandez-Rodriguez, Blanca M

AU - Ryner, Malin

AU - Kramer, Daniel

AU - Link, Jenny

AU - Ramanujam, Ryan

AU - Auer, Michael

AU - Buck, Dorothea

AU - Grummel, Verena

AU - Bertotti, Elisa

AU - Fissolo, Nicolas

AU - Oliver-Martos, Begoña

AU - Nytrova, Petra

AU - Khalil, Michael

AU - Guger, Michael

AU - Rathmaier, Sandra

AU - Sievers-Stober, Claudia

AU - Lindberg, Raija L P

AU - Hässler, Signe

AU - Bachelet, Delphine

AU - Aktas, Orhan

AU - Donnellan, Naoimh

AU - Lawton, Andy

AU - Hemmer, Bernhard

AU - Havrdova, Eva Kubala

AU - Kieseier, Bernd

AU - Hartung, Hans-Peter

AU - Comabella, Manuel

AU - Montalban, Xavier

AU - Derfuss, Tobias

AU - Sellebjerg, Finn

AU - Dönnes, Pierre

AU - Pallardy, Marc

AU - Spindeldreher, Sebastian

AU - Broët, Philippe

AU - Deisenhammer, Florian

AU - Fogdell-Hahn, Anna

AU - Sorensen, Per Soelberg

AU - ABIRISK Consortium

N1 - Copyright © 2018 Elsevier B.V. All rights reserved.

PY - 2019/1/15

Y1 - 2019/1/15

N2 - Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.

AB - Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.

KW - Antibodies, Neutralizing/blood

KW - Biological Assay

KW - Enzyme-Linked Immunosorbent Assay

KW - Female

KW - Humans

KW - Immunologic Factors/immunology

KW - Interferon-beta/immunology

KW - Male

KW - Multiple Sclerosis/blood

KW - Neutralization Tests/methods

U2 - 10.1016/j.jneuroim.2018.11.002

DO - 10.1016/j.jneuroim.2018.11.002

M3 - Journal article

C2 - 30447419

VL - 326

SP - 19

EP - 27

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

ER -

ID: 58577830